Skip to main content
Premium Trial:

Request an Annual Quote

New Products Posted to GenomeWeb: May 28, 2015

Qiagen Clinical Insight

Qiagen has launched Qiagen Clinical Insight, a bioinformatics content and software platform that clinical testing laboratories can use to interpret and report on genomic variants identified in next-generation sequencing data.

According to the company, the Clinical Insight platform provides tools for evaluating genomic variants in the context of published biomedical literature, professional association guidelines, publicly available databases and annotations, drug labels, and clinical trials. It enables clinicians rapidly classify variants, identify treatment options, and match patients to clinical trials. It also provides access to the Allele Frequency Community, a large repository of ancestral and ethnic diversity data.

The platform currently supports somatic and hereditary cancer testing.

Waters Vion IMS QTof Mass Spectrometer and Oasis PRiME HLB for Solid Phase Extraction

Waters has launched the Vion IMS QTof Mass Spectrometer. The benchtop tandem mass spec instrument features ion mobility to remove spectral interferences and generate collision cross-section values for every ion, giving scientists more information than they can get from traditional LC-MS experiments, the company said. The platform also features the REIMS Research System with iKnife sampling, combining direct-from-sample ionization with high-performance time-of-flight mass spectrometry.

Waters also introduced the Oasis PRiME HLB next-generation solid phase extraction product, designed to provide cleaner samples in less time and with less effort for LC and LC-MS analyses.  Laboratories can now process samples up to 40 percent faster and deliver samples that are up to 70 percent cleaner with fewer LC-MS matrix effects than samples prepared using other extraction techniques, the company said.

Strand Life Sciences StrandAdvantage Genomic Profiling Service
Strand Genomics said this week that it will introduce its expanded StrandAdvantage pan-cancer genomic profiling service at the American Society of Clinical Oncology meeting in Chicago next week. The new version of StrandAdvantage will include a panel that examines 152 genes and pathways known to be impacted by existing targeted cancer therapies plus additional chemotherapeutic toxicity and resistance data. The service provides oncologists with clinically actionable results beginning with a report on eight "standard-of-care" genes delivered to the oncologist within eight days. A full report is provided within 15 days that covers all major gene variants and pathways known to be impacted by existing targeted therapies.

For more recently launched products and services, please see the New Products page on our website.